RENEURON GROUP
ReNeuron Group engages in the research, development, and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.
RENEURON GROUP
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
1997-01-01
Address:
Guildford, Surrey, United Kingdom
Country:
United Kingdom
Website Url:
http://www.reneuron.com
Total Employee:
51+
Status:
Active
Contact:
+44 1483 302560
Email Addresses:
[email protected]
Total Funding:
166.42 M USD
Technology used in webpage:
Apple Whitelist GMap Equinix
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2007-07-27 | AmCyte | AmCyte acquired by ReNeuron Group | N/A |
Investors List
Woodford Investment Management
Woodford Investment Management investment in Post-IPO Equity - ReNeuron Group
Arthurian Life Sciences
Arthurian Life Sciences investment in Post-IPO Equity - ReNeuron Group
Matrix Corporate Capital
Matrix Corporate Capital investment in Post-IPO Equity - ReNeuron Group
Excalibur Fund Managers
Excalibur Fund Managers investment in Venture Round - ReNeuron Group
Official Site Inspections
http://www.reneuron.com Semrush global rank: 7.66 M Semrush visits lastest month: 447
- Host name: 225.76.189.35.bc.googleusercontent.com
- IP address: 35.189.76.225
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "ReNeuron Group"
Home - ReNeuron
ReNeuron is developing the next generation of engineered Exosomes. Utilising our stem cell-based technologies, targeting tissues of interest and delivering payloads of choice. Click here to access the presentation at Cell 2023 on 8 …See details»
ReNeuron - Wikipedia
ReNeuron is a UK-based stem cell research company whose shares were listed on the Alternative Investment Market, until it delisted in August 2024 after entering administration . Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases. As of 2010 ReNeuron was testing the effects of neural stem cells on spinal cords for neuroregenerationSee details»
Developing stem cell technologies to improve patients’ lives
ReNeuron Group plc Annual Report and Accounts 2021 ReNeuron Group plc Annual Report and Accounts 2021 30465-ReNeuron-AR2021.indd 3 06/08/2021 12:41:44. 30465 6 August 2021 …See details»
ReNeuron Reports Interim Results for Eight Patients with RP in …
Oct 18, 2019 · ReNeuron, a company developing stem-cell therapies for retinal diseases and other conditions, has announced evidence of efficacy from the Phase 2a clinical trial for its …See details»
ReNeuron Group Plc - LinkedIn
Our focus at ReNeuron is on our CustomEx exosome technology platform, producing exosomes with unique tissue targeting tropisms to deliver a payload of choice to a preferred cell type. Our mission...See details»
CORPORATE PRESENTATION - reneuron.com
The information contained in this document (“Presentation”) has been prepared by ReNeuron Group plc (the “Company”) and neither this Presentation, nor the information contained in it …See details»
ReNeuron Group — Differentiating in exosome drug …
Oct 7, 2022 · ReNeuron Group, a stem cell-derived exosome technology company, has presented encouraging preclinical data highlighting the enhanced drug delivery capability of its customisable exosome platform (CustomEx) over …See details»
RENEURON GROUP PLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for RENEURON GROUP PLC of BRIDGEND. Get the latest business insights from Dun & Bradstreet.See details»
ReNeuron Group (RENE): Re-initiation - Yahoo Finance
Nov 3, 2022 · ReNeuron is a UK-based stem cell research company now strategically re-focused on the development of its exosome drug delivery technologies. Recent encouraging preclinical proof-of-concept data...See details»
ReNeuron - VentureRadar
Website: http://www.reneuron.com/ Develops proprietary stem cell-based exosome technologies to create 'off the shelf' treatments for diseases with unmet needs, utilizing a unique delivery …See details»
ReNeuron Group - Crunchbase Company Profile
ReNeuron Group engages in the research, development, and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. A platform for developing customizable exosomes for targeted …See details»
A leader in stem cell and exosome technologies - reneuron.com
ReNeuron is a UK-based proprietary stem cell and exosome technologies company harnessing its unique technologies to develop ‘off-the-shelf’ treatments for disease with significant unmet …See details»
Company ReNeuron Group Plc London S.E. - MarketScreener.com
Dec 3, 2015 · ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet …See details»
ReNeuron Announces Presentation of Updated Efficacy and Safety …
Apr 26, 2019 · ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for …See details»
ReNeuron Group - Edison Group
ReNeuron is a UK biotech company developing allogeneic cell therapies. The first pivotal Phase IIb trial for CTX neural stem cells for chronic stroke disability is underway. Human retinal …See details»
Company ReNeuron Group plc - MarketScreener.com
Dec 3, 2015 · ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet …See details»
ReNeuron leaving AIM exchange after missing fundraising goal
Aug 30, 2024 · ReNeuron has joined the long list of biotechs to leave London’s AIM stock market. The stem cell biotech is letting go of its listing after money troubles persuaded it to free itself …See details»
INVESTOR PRESENTATION - reneuron.com
Well-funded following recent £17.5m capital raise. Extended RP Phase 2a clinical data read-outs and exosome pre-clinical proof-of-concept data expected during 2021. Potential as drug …See details»
Reneuron: Uses, Dosage, Side Effects, FAQ - MedicinesFAQ
Sep 19, 2023 · Reneuron is a selective serotonin reuptake inhibitor (SSRI) and as the name suggests, it exerts it's therapeutic effect by inhibiting the presynaptic reuptake of the …See details»
21 January 2014 AIM: RENE Positive pre-clinical data ... - ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development business. Its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly …See details»